Tricuspid Regurgitation (TR) afflicts more than 3 million patients in the United States and Europe, thus making the TR patient population about 2/3 of the size of the MR (Mislal Regurgitation) patient population. Nonetheless, Tricuspid is The Forgotten Valve.

Today's standard of care for TR is medical management. Surgical intervention is very high risk. In fact, in-hospital death post-cardiac surgery for isolated TR can be as high as 37%.

And, TR patients tend to be non-compliant with their medications. Thus, TR and related complications induce huge healthcare spending due to frequent re-hospitalizations. Furthermore, TR leads to chronic renal failure and end-stage dialysis. Therefore, there is a significant unmet need for a transcatheter solution to treat TR.

Interventional cardiologists are asking for a TTVR (Transcatheter Tricuspid Valve Repair) solution to treat patients suffering from TR and who have been considered very high-risk by the cardiac surgeon.

4Tech’s TriCinch™ system is designed to be a clinically effective and cost-effective procedure to enhance the quality of life of a patient suffering from Tricuspid Valve disease. All of the major medical device companies are looking for technologies, such as TTVR, to complete their Structural Heart Disease portfolio. TriCinch™ is the most clinically advanced TTVR system.

The 4Tech TriCinch™ TTVR System is the world’s first to reach the clinical milestone of six months follow-up on patients who were at “very high risk” for surgical treatment of TR, and who therefore benefited from a transcatheter repair of their Tricuspid heart valve.

What the Experts Are Saying About the Clinical Need for Transcatheter Tricuspid Valve Repair (TTVR)

Prof. Dr. Francesco Maisano
Head, Department of Cardiovascular Surgery, Zurich University Hospital Zurich, Switzerland.

“A typical TR patient has been in the chain of care for 15 years, with frequent hospitalizations. They are not candidates for TR surgery because of their frail health.” (NOTE: Prof. Maisano is a co-founder of 4Tech.)

Dr. Hugo Vanermen
Cardiac Surgeon Brussels, Belgium.

“TR greatly impacts the rate of hospitalization, inducing huge costs into the system. Surgery is very high-risk, and there is a significant unmet clinical need for a percutaneous solution.” (NOTE: Dr. Vanermen is a co-founder of 4Tech.)

Dr. Azeem Latib
Interventional Cardiologist San Raffaele Hospital Milan, Italy

“We must develop an effective, simple device and simple procedure to restore the quality of life for patients who are suffering from Tricuspid valve disease and who are too high-risk for surgery.”

CAUTION: The 4Tech TriCinch™ System for Transcatheter Tricuspid Valve Repair is in the early phase of development. It will not be available in the USA for clinical trials until further notice and is NOT available for sale.